Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There are two well-characterized antigen-antibody systems which relate specificially to viral hepatitis B. Tests for HBsAg and anti-HBs are readily available and of great benefit to the diagnosis, prevention and understanding of hepatitis B. Tests for HBcAg and anti-HBc are still research techniques which requires further development before they can be used at the level of everyday medical practice. HBsAg in an individual indicates that he harbors the virus of hepatitis B; it may be present in the absence of liver disease or be found in association with both acute and chronic type B hepatitis. The presence of HBsAg also suggests that HBV may be causally related to some cases of periarteritis nodosa, chronic glomerulonephritis, and hepatoma. Although HBV is readily transmitted in blood, the major portion of post-transfusion hepatitis now appears to be serologically unrelated to either the hepatitis B virus ("serum") or the hepatitis A virus ("infectious"); the etiology of these cases is currently undetermined. There is increasing evidence that HBV may be transmitted by modes other than blood, but the exact mechanisms of such transmission is not established. The combined transmission of HBV by blood and other routes has resulted in a large number of persistent carriers of HBsAg in the world. There is no current method to alter this carrier state. The hepatitis risk of such persistent carriers to their personal and professional contacts is under investigation.
 ...
PMID:The clinical significance of hepatitis B virus antigens and antibodies. 4 64

Infections with hepatitis A and B viruses are common in all parts of the world and constitute a major public health problem. The identification of specific antigenic markers of these viruses has led to the development of sensitive laboratory tests. These, in turn, have resulted in a better understanding of the epidemiology, pathogenesis, immunology, and the nature of these common infections. In the case of hepatitis type B, laboratory tests revealed a persistent carrier state of the surface antigen in some 120-175 million people and established the significance of hepatitis B virus in the pathogenesis of serious chronic liver disease, including a strong association with primary hepatocellular carcinoma in tropical and some subtropical regions. In addition, the specific diagnosis of hepatitis types A and B has revealed a previously unrecognized form of hepatitis which is clearly unrelated to either type. This new form of infection of the liver is now the most common type of hepatitis after the transfusion of blood and blood products in some areas of the world and it also appears to be an important cause of sporadic hepatitis, particularly among adults.
 ...
PMID:The three type of human viral hepatitis. 7 70

The prevalence of antibody to the hepatitis A antigen (anti-HAV) has been studied in Senegal, among patients suffering from primary hepatocellular carcinoma (PHC) and among healthy blood donors. Anti-HAV was found in 62.5% of 64 cases of PHC as compared to 64% of 50 blood donors. Anti-HAV was as prevalent among PHC patients who evidenced chronic hepatitis B infection as among those without markers of chronic hepatitis B infection. These data suggest that hepatitis A infection is not associated with PHC in Senegal.
 ...
PMID:Hepatitis A infection and primary hepatocellular carcinoma. 22 67

Hepatitis A virus (HAV) was isolated directly from human feces and propagated serially in an HBsAg producing human hepatoma cell line. No cytopathic effect was observed in the tissue culture and no detectable amounts of HAV were present in the tissue culture supernatant fluid. However, increasing amounts of hepatitis A antigen (HAAg) were detected by radioimmunoassay in the cell extracts obtained by freezing and thawing of cells. Specificity of the HAAg determination was shown by neutralization with convalescent sera of marmosets experimentally infected with the MS-1 strain of hepatitis A and by the absence of this neutralization with preinoculation sera. HAAg was first detected after four weeks in the cell extract of infected cultures after inoculation of 10(2)--10(4) tissue culture infectious doses of HAV from second passage.
 ...
PMID:Propagation of human hepatitis A virus in a hepatoma cell line. 23 98

Since the detection of hepatitis B virus (HBV) in the 1960s and hepatitis A virus in the 1970s, a considerable proportion of infections of (probably viral) hepatitis could not be classified. About 90% of transfusion-related hepatitis was identified as non-A/non-B. In 1988 investigators from the Chiron Company (USA) detected the non-A, non-B agent and named it hepatitis C virus (HCV). An anti-HCV antibody assay (ELISA) and subsequently confirmation tests (immunoblot and polymerase chain reaction) were developed. HCV infection results in a chronic carrier state of the virus in about 80%. Almost all HCV carriers have, irrespective of their liver function tests, histologic signs of chronic hepatitis and/or liver cirrhosis. Chronic HCV infection is, like HBV, also associated with the development of hepatocellular carcinoma. Most HCV carriers are infected by parenteral routes (intravenous drug use, blood transfusion, tattooing). Intravenous drug users and haemophilia patients have the highest risk (80-90%) of becoming infected. Sexual and perinatal transmission does not play an important role in spreading the infection. Antiviral therapy (alpha-interferon) in patients with chronic hepatitis C will normalize liver function tests in about 25% of the cases, but it is unclear if the HCV carrier state will disappear and if liver cirrhosis will be prevented. At present no specific immunoglobulin or vaccine preparations are available to prevent the HCV infection.
 ...
PMID:New developments in hepatitis C. 129 54

Human hepatitis B virus (HBV) carriers run an increased risk of hepatocellular carcinoma (HCC), where the expression of HBV genes play the most important role in the initial stage of hepatocarcinogenesis. As the integration of HBV DNA into the cellular DNA of HCC as well as chronic hepatitis was demonstrated very frequently, the virus-cell fusion gene was considered to be most essential for hepatocarcinogenesis. Among the virus-cell fusion genes, the X gene is known to function as a transactivator for viral and cellular genes at the time of chronic infection. One mechanism for hepatocarcinogenesis that appears particularly reasonable is transactivation of cellular oncogenes by the X-cell fusion protein. In 1990, we found a part of the amino acid sequences in the X protein to be highly homologous to functionally essential sequences in the Kunitz domain, characteristic of Kunitz-type serine protease inhibitors. It has been recently demonstrated that X protein expressed in E. coli or from the in vitro translation system binds to a specific serine protease from the liver cells. These results indicate that transactivation function of X protein may be exerted by acting as a protease inhibitor analogue to control the proteolytic pathway of cellular transcription factor(s). On the other hand, viral hepatitis resulting from viruses other than hepatitis A virus and HBV has been referred to as non-A, non-B hepatitis. In 1989, the viral genome was molecularly cloned as a positive-strand RNA having about 10 kb in size and named as hepatitis C virus (HCV). Details of genetic structure and mechanism of expression are currently under investigation at molecular level.
 ...
PMID:[Gene expression of hepatitis viruses in the liver and hepatocarcinogenesis]. 132 91

Recent advances in epidemiology, virology, of clinical of hepatitis are presented in the paper. The authors pointed out that hepatitis A never becomes chronic. On the other hand, with hepatitis B or B and D, evolution to chronicity is possible. Two distinct forms of non-A non-B hepatitis are now distinguished: parenterally transmitted non-A non-B hepatitis, mainly due to hepatitis C virus; enterically transmitted non-A non-B hepatitis mainly due to hepatitis E virus. C virus hepatitis is characterized by a frequent course to chronic hepatitis, cirrhosis and hepatocellular carcinoma. Chronic forms are associated with the presence of anti-HC antibodies in the serum. These antibodies are rarely present in the acute stage of the disease. Hepatitis E is almost exclusively encountered in developing countries. Like with A virus hepatitis, chronicity never occurs. However, fulminant hepatitis is possible in pregnant women in the third trimester of pregnancy. There is no routine serological test. Development of vaccines against A, E and C viruses can be expected very soon. There is no specific treatment of acute viral hepatitis.
 ...
PMID:[Acute viral hepatitis--present status and perspectives]. 136 29

Sulphated polysaccharides such as iota-, lambda- and kappa-carrageenans showed a potent inhibitory effect on the replication of hepatitis A virus (HAV) in the human hepatoma cell line PLC/PRF/5. No cytotoxic effects were detected with concentrations of carrageenans up to 200 micrograms/ml. The selectivity indices of these substances, calculated as the ratio of the dose that reduced the number of viable cells to 50% (CD50) to the effective dose that inhibited 50% of viral antigen expression (ED50), were greater than 400 with iota-carrageenan, greater than 222 with lambda-carrageenan and greater than 10 with kappa-carrageenan. The selectivity index of ribavirin (reference substance) was only 5. The 3 types of carrageenans resulted in concentration-dependent reduction of HAV-antigen expression and HAV infectivity. lota-and lambda-carrageenan emerged, from the present study, as promising candidates for chemotherapy of acute hepatitis A.
 ...
PMID:Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. 166 74

The seroepidemiology of HBV and HCV infections in the patients with acute and chronic liver diseases in Jakarta was investigated. The sera from 141 cases with acute hepatitis, 176 liver cirrhosis and 70 hepatocellular carcinoma (HCC) were examined. Anti-HA IgM, HBsAg, anti-HBc IgM and anti HCV (Ortho) were detected by Elisa method. In acute hepatitis, 83 cases (58.9%) out of 141 cases were hepatitis A and 9 cases (6.4%) hepatitis B. The others were diagnosed non-A, non-B (NANB) hepatitis and anti-HCV in 4 cases (11.8%) out of 34 cases with NANB hepatitis was positive. The low prevalence of anti-HCV in acute NANB hepatitis seems to be due to inadequate date of serum sampling. HBsAg and anti-HCV in liver cirrhosis were positive 36.5% and 73.9% respectively, including 22.7% of double infection. HBsAg and anti-HCV in HCC were 58.6% and 34.2%, including 17.1% of double infection. In 16.7% fo chronic liver disease (liver cirrhosis and HCC), neither HBsAg nor anti-HCV were detected.
 ...
PMID:The prevalence of antibody to hepatitis C virus (anti-HCV) in patients with acute and chronic liver diseases in Jakarta, Indonesia. 190 63

A survey was performed to investigate HBV and HCV infection in Ujung Pandang. The total number of subjects was 406; 196 blood donors, 78 cases of acute hepatitis, 43 of chronic hepatitis, 58 of liver cirrhosis and 31 of hepatocellular carcinoma cases. HBsAg, anti-HBs and anti-HBc as HBV markers and anti-HCV (ELISA, Ortho) as an HCV marker were tested. Positive rates of HBsAg and anti HCV among blood donors were 7.1% and 3.1% respectively, and there was no significant difference among age groups. Donors negative for all viral markers accounted for 21.4%. Of acute hepatitis cases, 18 (23.1%) cases were hepatitis A and 8 (10.3%) cases were hepatitis B, one case of which was considered to be double infection. Acute exacerbation cases of HBV carriers were 16 (20.5%), of which 6 cases were positive for HCV antibody. Those diagnosed non-A, non-B hepatitis were 37 (47.4%), of which 3 cases where positive for HCV antibody. Blood samples from all of acute hepatitis cases were obtained within 1 week after onset of the disease, thus, it was not possible to accurately assess prevalence of hepatitis C. Positive rates on HBsAg among chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 25.4%, 32.8% and 35.5% respectively, while those for HCV antibody were 16.3%, 43.1% and 35.5% respectively. Positive rates of HBsAg and HCV antibody for overall chronic liver diseases were 31.1% and 32.6%, and 14 (10.6%) were positive for both markers.
 ...
PMID:Hepatitis B and C virus infection in Ujung Pandang, Indonesia. 190 64


1 2 3 4 5 6 7 8 9 10 Next >>